Ptc Therapeutics (PTCT) Capital Leases (2020 - 2025)

Ptc Therapeutics' Capital Leases history runs 6 years deep, the most recent figure standing at $3.0 million for Q4 2025.

• In Q4 2025, Capital Leases fell 80.74% year-over-year to $3.0 million; the TTM figure through Dec 2025 stood at $3.0 million (down 80.74% YoY), while the FY2025 annual figure was $3.0 million, down 80.74% from the prior year.
• Capital Leases for Q4 2025 stood at $3.0 million, down from $13.8 million in the prior quarter.
• The five-year high for Capital Leases was $20.1 million in Q3 2021, with the low at $3.0 million in Q4 2025.
• The 5-year median for Capital Leases is $17.2 million (2023), against an average of $16.5 million.
• The sharpest annual moves came in 2022 and 2025: Capital Leases fell 6.75% in 2022, then sank 80.74% in 2025.
• Ptc Therapeutics' Capital Leases stood at $20.1 million in 2021, then fell by 7.09% to $18.7 million in 2022, then slipped by 7.98% to $17.2 million in 2023, then fell by 9.37% to $15.6 million in 2024, then tumbled by 80.74% to $3.0 million in 2025.
• Business Quant data shows PTCT's Capital Leases at $3.0 million in Q4 2025, $13.8 million in Q3 2025, and $13.8 million in Q2 2025.